# US 2016/0354320 A1 · Drug loaded polymeric nanoparticles and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354320 A1
- Document ID: US20160354320A1
- Status: Published application
- Kind: A1
- Application number: 15/016,452
- Filed: 2016-02-05
- Published: 2016-12-08
- Earliest claimed: 2011-05-31
- Assignees: BIND Therapeutics, Inc.
- Applicants: BIND Therapeutics, Inc.
- Inventors: Stephen E. Zale
- Web page: https://patentgrep.com/patent/US20160354320A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5192: {Processes}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

## Claims

### Claim 1

A therapeutic nanoparticle comprising:
about 0.2 to about 35 weight percent of a therapeutic agent;
about 10 to about 99 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer; and
about 0 to about 75 weight percent poly(lactic) acid or poly(lactic) acid-co-poly (glycolic) acid.

### Claim 2 (depends on 1)

The therapeutic nanoparticle of claim 1 wherein said therapeutic agent is a taxane.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the hydrodynamic diameter of therapeutic nanoparticle is about 60 to about 120 nm.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the therapeutic nanoparticles substantially retains the therapeutic agent for at least 5 days at 25° C.

### Claim 7 (depends on 1)

The therapeutic nanoparticle of claim 1, comprising about 10 to about 20 weight percent of a taxane agent.

### Claim 8 (depends on 1)

The therapeutic nanoparticle of claim 1, comprising about 40 to about 90 weight percent poly(lactic) acid-poly(ethylene)glycol copolymer.

### Claim 9 (depends on 8)

The therapeutic nanoparticle of claim 8, wherein said poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to 100 kDa and poly(ethylene)glycol having a number average molecular weight of about 2 to about 10 Da.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the particle substantially immediately releases less than about 5% of the therapeutic agent over 1 hour when placed in a phosphate buffer solution at room temperature.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The therapeutic nanoparticle of claim 1, wherein the particle substantially immediately releases less than about 10% of the therapeutic agent when placed in a phosphate buffer solution at either 37° C. or room temperature.

### Claim 14 (depends on 1)

The therapeutic nanoparticle of claim 1 comprising about 30 to about 50 weight percent PLA-PEG, about 30 to about 50 weight percent PLA or PLGA, and about 15 to about 25 weight percent active agent.

### Claim at position 15

15-18. (canceled)

### Claim 19 (depends on 1)

The therapeutic nanoparticle of claim 1, further comprising about 0.2 to about 30 weight percent PLA-PEG functionalized with a targeting ligand.

### Claim 20 (depends on 1)

The therapeutic nanoparticle of claim 1, further comprising about 0.2 to about 30 weight percent poly (lactic) acid-co poly (glycolic) acid-PEG-functionalized with a targeting ligand.

### Claim 21 (depends on 19, 20)

The therapeutic nanoparticle of claim 19 or 20, wherein the targeting ligand is covalently bound to the PEG.

### Claim 22 (depends on 1)

The therapeutic nanoparticle of claim 1, further comprising about 0.2 to about 10 weight percent PLA-PEG functionalized with a targeting ligand.

### Claim 23 (depends on 1)

The therapeutic nanoparticle of claim 1, further comprising about 0.2 to about 10 mole percent PLA-PEG-GL2 or poly (lactic) acid-co poly (glycolic) acid-PEG-GL2.

### Claim 24 (depends on 1)

The therapeutic nanoparticle of claim 1, further comprising a polymeric compound selected from:
wherein R1 is selected from the group consisting of H, and a C1-C20 alkyl group optionally substituted with halogen;
R2 is a bond, an ester linkage, or amide linkage;
R3 is an C1-C10 alkylene or a bond;
x is 50 to about 1500;
y is 0 to about 50; and
z is about 30 to about 200.

### Claim at position 22

25-34. (canceled)

### Claim 35 (depends on 1)

A composition comprising a plurality of nanoparticles of claim 1, and a pharmaceutically acceptable excipient.

### Claim 36

(canceled)

### Claim 37

A pharmaceutical composition comprising:
a plurality of polymeric nanoparticles each comprising about 0.2 to about 35 weight percent of a therapeutic agent, about 70 to about 99 weight percent of a biocompatible polymer, and optionally a fatty alcohol; wherein the biocompatible polymer is selected from the group consisting of: a) poly(lactic) acid-poly(ethylene)glycol copolymer; b) poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer; c) a combination of a) or b) and poly (lactic) acid or polylactic-co-glycolic acid copolymer; and
a pharmaceutically acceptable excipient.

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the pharmaceutically acceptable excipient is sucrose.

### Claim at position 27

39-47. (canceled)
